Non-Invasive Drug Treatment to Remain Most Preferred Radiation Proctitis Treatment Approach: Fact.MR Study
07 Apr 2021
Radiation Therapy
High reliance on chemotherapy and other radiation based cancer treatment approaches are accentuating prevalence of radiation proctitis, prompting patients to opt for advanced therapeutic approaches
Fact.MR, Rockville MD: Award winning market research company Fact.MR’s ongoing study on the global radiation proctitis treatment market anticipates a positive outlook for FY 2021-22, underpinned by increasing emphasis on radiation therapy to treat pelvic malignancies across key geographies. Despite a blip experienced during the peak of the pandemic crisis, the market is slated to emerge strong, posting substantial gains in forthcoming years.
According to popular studies, likelihood of chronic proctitis as a side effect amongst radiotherapy patients is about 5%. Furthermore, an extensive study published by the European Organization for Research and Treatment of Cancer (EORTC) and the Radiotherapy Oncology Group (RTOG) reports a 3-40% prevalence rate of radiation proctitis amongst patients who avail external beam radiation. However, a series of intensity-modulated radiation therapy (IMRT) trials report that occurrences vary from 2-10%, and that of particle radiotherapy at less than 1%.
Manufacturers are expected to discover fresh revenue pools especially across the rectal cancer segment, as one of the most common symptoms of radiation proctitis is rectal bleeding. Consequently, healthcare providers have been concentrating on endoscopic approaches to stem this problem. An effective approach has been implementation of medical lasers which help coagulate or ablate the tissue. An NCBI study concluded that patients suffering from radiation proctitis who have received laser treatment experienced a major improvement. Daily rectal bleeding rates declined from 85% to 11%, which was highly statistically significant.
“While radiation therapy has significantly improved cancer patient survival rates in the recent past, high reliance on the same have heightened concerns regarding possible long-term impacts on human health. This has only served to underscore the importance of radiation proctitis, providing a wide platform for key manufacturers to offer highly advanced treatment approaches,” remarks the Fact.MR analyst.
Request a report sample to gain comprehensive insights at
Key Takeaways from Fact.MR’s Radiation Proctitis Treatment Market Study
By indication, acute radiation proctitis treatment to remain the primary application area
Oral radiation proctitis treatment to remain the most preferred therapy type through 2021 and beyond
By type, non-invasive sucralfate drug treatment to capture significant attention
By distribution channel, hospital pharmacies are expected to capture the majority share
US to experience high radiation proctitis treatment, owing to high treatment seeking rates for colon and rectal cancers
High prevalence rates of cervical cancers to stimulate treatment procedures across the UK
Germany to open up new revenue ecosystems, attributed to high ovarian cancer treatment procedures
Heightened expenditure on gynecological cancer treatment and research further growth prospects across India & China
Radiation Proctitis Treatment Market- Prominent Drivers
High prevalence rates of cervical, prostate and rectal cancers is augmenting treatment procedures for the same, heightening growth prospects
Increased reliance on radiation therapy for better patient outcomes is likely to enhance advanced radiation proctitis treatment adoption
Governments worldwide are providing increasing assistance with regards to research funding to develop new therapeutic approaches
Radiation Proctitis Treatment Market- Key Restraints
Inadequate awareness regarding the dangers of radiation proctitis is limiting adoption across several regions
Sluggish healthcare infrastructure development in emerging economies renders it unaffordable for key healthcare institutions to invest in advanced radiation proctitis treatment options
Discover more about the Radiation Proctitis Treatment market with figures and data tables, along with the table of contents. You will also find detailed market segmentation on
Competitive Landscape
Chugai Pharmaceutical Co. Ltd., GlaxoSmithKline Plc, Dr. Reddy’s Laboratories Ltd., Allergan Plc, Northeast Pharmaceuticals, Reckitt & Benckiser, Guangdong Huanan Pharma, Sun Pharmaceutical Industries and Nanjing Pharmaceutical Factory Co. Ltd. are some prominent radiation proctitis treatment solutions providers profiled in Fact.MR’s extensive study.
The aforementioned market players rely on a slew of expansion strategies, including offering new products, collaborating with healthcare research institutions, capacity expansion measures and strategic partnerships to enhance their market footprint across key regions.
More Insights on the Radiation Proctitis Treatment Market
Fact.MR, in its new offering, brings to fore an unbiased analysis of the global radiation proctitis treatment market, presenting historical demand data (2016-2020) and forecast statistics for the period, 2021-2031. The study divulges compelling insights on the radiation proctitis treatment market based on indication (acute radiation proctitis treatment and chronic radiation proctitis treatment), therapy (oral therapy, rectal instillation therapy, thermal therapy and hyperbaric oxygen therapy), type (non-invasive and invasive), route of administration (oral and intravenous) and distribution channel (hospital pharmacies, drug stores, retail pharmacies and online pharmacies) across seven major regions (North America, Latin America, Europe, South Asia, East Asia, Oceania and Middle East & Africa).
Request For No-Obligation Table Of Content
Explore Fact.MR’s Coverage on the Healthcare Domain
Olaparib API Market: Fact.MR’s ongoing research project on the olaparib API market delves into detailed observations regarding the prominent expansion prospects expected to present themselves throughout the forthcoming decade. The study incorporates an in-depth analysis of the prominent market drivers, restraints and opportunities, along with statistics on key segments’ scope across prominent geographies.
Cough Systems Market: The global cough systems market is likely to escalate to new heights, amid rising prevalence of various respiratory disorders, according to an ongoing study on the market by Fact.MR. The report sheds light on prominent segments’ growth dynamics across highly lucrative regions, along with an in-depth competitive landscape for the forecast period 2021-2031.
Byler Disease Market: Fact.MR’s incumbent study on the byler disease market brings to the fore important growth dynamics which are expected to shape future expansion trajectory for the decade until 2031. It provides an exhaustive analysis of the market’s key drivers, opportunities and limitations across prominent geographical locations and segments.
About Fact.MR
Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner.
Contact:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E: sales@factmr.com
Follow Us: LinkedIn | Twitter
Market Intelligence Services: Marketngage.com
Source: Fact.MR
Organizations
Indications
Targets
-Drugs
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.